Gilead’s end-stage confirmatory trials of bladder cancer drug fail
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.
Drugs
Health
Pharma
Drugs
Health
Medical
J&J stops trials on drug to treat muscle-invasive bladder cancer
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results
Drugs
Health
Pharma
EC approves Merck’s bladder cancer combination therapy in adults
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.
Drugs
Health
Pharma
USFDA grants approval for ImmunityBio’s bladder cancer drug
HQ Team April 23, 2024: Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the.
Drugs
Health
Pharma
J&J’s metastatic bladder cancer drug gets full FDA approval
HQ Team January 21, 2024: The FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical.
Drugs
Health
Pharma
Roche’s under-the-skin cancer injection gets Britain’s nod
HQ Team August 30, 2023: Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency. Tecentriq.
Drugs
Medical
FDA approves gene therapy for treatment of high-risk bladder cancer
The FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy for the treatment of high-risk bladder cancer.